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Abstract:  The influence of dynamics on solution state structure is a widely overlooked 
consideration in chemistry.  Variations in Gd3+ chelate hydration with changing coordination 
geometry and water exchange kineticssubstantiallyimpact the effectiveness (or relaxivity) of 
mono-hydrated Gd3+ chelates as T1-shortening contrast agents for MRI.  Theory shows that 
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relaxivity is highly dependent upon the Gd3+-water proton distance (rGdH) and yet this distance is 
almost never considered as a variable in assessing the relaxivity of a Gd3+ chelate as a potential 
contrast agent.  The consequence of this omission can be seen when considering the relaxivity of 
isomeric Gd3+ chelates that exhibit different water exchange kinetics.  The results described 
herein show that the relaxivity of a chelate with ‘optimal’ water exchange kinetics is actually 
lower than that of an isomeric chelate with ‘sub-optimal’ water exchange.  When the rate of 
molecular tumbling of these chelates is slowed, an approach that has long been understood to 
increase relaxivity, the observed difference in relaxivity is increased with the more rapidly 
exchanging (‘optimal’) chelate exhibiting lower relaxivity than the ‘sub-optimally’ exchanging 
isomer.  The difference between the chelates arises from a non-field dependent parameter: either 
the hydration number (q) or rGdH.  For solution state Gd3+chelates, changes in the values ofq and 
rGdH are indistinguishable. These parametric expressions simply describe the hydration stateof 
the chelate – i.e. the number and position of closely associating water molecules. The hydration 
state (q/rGdH6) of a chelate is intrinsically linked to its water exchange ratekexand the 
interrelationof these parameters must be considered when examining the relaxivity of Gd3+ 
chelates.  The data presented herein indicates that the changes in the hydration parameter (q/rGdH) 
associated with changing water exchange kinetics has a profound effect on relaxivity and suggest 
that achieving the highest relaxivities in monohydrated Gd3+ chelates is more complicated than 
simply “optimizing” water exchange kinetics. 
 
Introduction 
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Chelates of Gd3+are now routinely administered as contrast agents for MRI.  After intravenous 
injection these chelates extravasate through the pores at the endothelial junctions of the 
vasculature into interstitial space.  Time dependent modulation of the dipolar interactions 
between the seven unpaired electrons of Gd3+ and proximate water protons leads to a shortening 
of the water proton longitudinal relaxation time constant (T1). In T1-weighted MR images this 
results in enhanced signal intensity in those regions to which the agent is distributed.  For agents 
that are currently in clinical use, distribution is a function of a number of vasculature 
characteristics, such as blood flow and pore size; and the size of the agent. The limited criteria by 
which these agents discriminate between tissue types limits the diagnostic information that can 
be obtained by administering these contrast agents. These limitations have provoked the idea of a 
new class of contrast agent: so-called “targeted agents” would possess a structural component 
that is designed to bind to a biomarker associated with a disease of interest.1  Binding of the 
agent will increase the localization of the agent in regions where that biomarker is more 
abundant, thereby increasing MR signal intensity of regions associated with the disease. Binding 
has one further effect: it will slow the agent’s rate of molecular tumbling, characterized by the 
correlation time τR. 
The theory of paramagnetic relaxation given by the Solomon-Bloembergen-Morgan (SBM) 
equations (equations 1-3) describes the relaxation of water protons that occurs through exchange 
of water molecules coordinated directly to the paramagnetic metal center.2-6  These equations tell 
us that reducing the rate of molecular tumbling (making τR longer) will afford a more effective 
contrast agent.7-9  This is critical because the Gd3+ chelates that are currently used clinically have 
high detection limits; a typical dose (0.1 mmolkg-1) equates to about 4.5 g of agent in a single 
bolus for a 70 kg human.  Clearly, if biomarkers of disease, which are present only in very low 
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abundance, are to be detected by MRI then it is absolutely critical that the detection limit of any 
“targeted agent” be much lower than those of agents currently employed.  To this end the SBM 
equations have been used to guide research into improving the function of MRI contrast agents. 
These equations reveal several parameters that may be manipulated by the chemist to control the 
effectiveness of an agent – defined as the longitudinal relaxivity, r1.  From the SBM equationsτR 
is found to limit the relaxivity of low molecular weight clinical agents. τR is readily made longer 
either by increasing the size of the agent, or by coupling its molecular motion to that of a large 
(or stationary) structure such as a protein or cell.  However, it is commonly found that when τR is 
made longer the relaxivity of a Gd3+ chelate is subsequently limited by the kinetics of inner-
sphere water exchange.10If τM, the residence lifetime of a water molecule on Gd3+, is too long 
then the coordination site on Gd3+is needlessly occupied by a ‘relaxed’ water molecule 
preventing relaxation of other water molecules, slowing the catalysis of bulk relaxation by the 
relaxation agent. This is the situation that prevails in all clinically approved Gd3+ chelates; if the 
limiting effect of τR is lifted then slow water exchange kinetics become limiting and the highest 
relaxivities are not realized.10  This realization has prompted considerable research effort into the 
development of more rapidly exchanging Gd3+ chelates that would, in principle, afford the 
highest relaxivities if the limiting effect of τR were lifted. 
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Several other parameters expressed in the SBM equations are also potentially under the control 
of the chemist.  Relaxivity scales proportionally with the number of water molecules coordinated 
directly to the Gd3+ ion, q, so increasing the number of water molecules directly coordinated to 
Gd3+ will afford higher relaxivities.  However, increasing the number of vacant coordination 
sites on Gd3+is also found to reduce the stability of the chelate.  Unchelated, the Gd3+ ion is quite 
toxic to mammals (LD50 ~ 0.35 mmolkg-1, i.v. in mice)11 and must therefore be administered in 
the form of a kinetically and thermodynamically robust chelate.10,12  In all clinically approved 
agents the Gd3+ ion is chelated by an octadentatepolyaminocarboxylate ligand (DTPA or a 
derivative, or DOTA or a derivative) and this leaves one coordination site available for 
occupation by water.  Opening additional coordination sites to water can cause the stability 
constant of a chelate to drop by as much as 3 orders of magnitude;13 suggesting that in practice, 
with perhaps a few exceptions,14-16 only q = 1 chelates are suitable for in vivo use. 
The recent observation of nephrogenic systemic fibrosis (NSF) in some renally compromised 
patients after administration of DPTA-based contrast agents further highlights the importance of 
chelate stability as a consideration in contrast agent development.17,18  Even though Gd3+ chelates 
derived from DTPA are q = 1 chelates, it is now generally accepted that they are not sufficiently 
robust to survive prolonged in vivo residence completely intact and are only safe if the entire 
dose is excreted rapidly.12,19-21  Targeted imaging applications also envisage prolonged in vivo 
residence lifetimes and as such Gd3+ chelates derived from DTPA should not be considered 
suited for the purpose.  The Gd3+ chelates of DOTA and its derivatives are more 
thermodynamically stable and more kinetically robust than their DTPA counterparts.22  They are 
more suitable for applications that require prolonged in vivo lifetimes, and controversy surrounds 
the isolated cases in which GdDOTA has been associated cases of NSF.23  In general, DOTA 
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derivatives are considered sufficiently stable for prolonged in vivo residence lifetimes, and 
therefore for targeted applications.  A further advantage of DOTA-derived chelates is the 
superior electron spin relaxation characteristics (T1e and T2e) of these chelates.  Electron spin 
relaxation is sometimes cited as another modifiable parameter that regulates relaxivity.  
However, even though considerable effort is being made to better understand this parameter,24-26 
at present its relationship with coordination chemistry is vague at best and at present the chemist 
is really faced with accepting what a given chelate provides.  However, in general DOTA 
derivatives are on the whole found to exhibit somewhat more favorable electron spin relaxation 
characteristics than their DTPA-based counterparts.27 
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Chart 1. 
Finally, one further parameter that also relates to hydration of the chelate can potentially have 
a profound effect upon relaxivity.  The distance from the metal to the inner sphere water protons, 
rGdH, is most widely viewed as a fixed value. In spite of this, the value used in the calculations 
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and fitting of relaxation data of Gd3+ chelates varies quite a bit; with values anywhere from 2.9 to 
3.1 Å commonly used.28  Given that relaxivity scales to the negative sixth power of rGdH, even 
small changes in this value would be expected to have profound effects on relaxivity.Parker and 
co-workers have demonstrated that faster water exchange kinetics are associated with weaker 
(i.e. longer) Gd3+-OH2bonds.29,30  Our own results suggest that differences in rGdHassociated with 
differing water exchange rates maynot be confinedsolely to consideration of “bond” distances 
but that the differences in rGdH may be even greater in solution.31-33These differences in rGdH are 
comparatively small – certainly less than the range of values commonly employed in the 
published data analyses.  Such small variations in rGdH are very difficult to quantify – they are 
less than the reported uncertainty in ENDOR measurements for instance,34and yet they could be 
large enough that they significantly impact relaxivity. 
Several research groups around the world, including ourselves, have developed q = 1 Gd3+ 
chelates that possess very fast water exchange kinetics.35-39 However, our chosen approach is 
unique in that in addition to a chelate with very fast water exchange kinetics the same methods 
can be applied to generate an isomeric chelate with slower water exchange kinetics.33,40  This 
allows us, for the first time, to compare the effects of accelerating inner-sphere water exchange 
on relaxivity.  To achieve this aim in slowly tumbling chelates, we have prepared prototypical 
targeted contrast agents that employ a simple hydrophobic group that will cause the agent to bind 
to various slowly tumbling systems, such as human serum albumin (HSA).  The advantages of 
this approach are that it is easy to effect and binding to HSA is comparatively well understood; it 
also allows our results to be compared to those obtained for related systems that also bind HSA. 
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Results and Discussion 
Gd3+ chelates of DOTA-type ligands can exist in two coordination geometries: a square 
antiprism (SAP) and a twisted square antiprism (TSAP).  It has long been appreciated that the 
water exchange kinetics of the TSAP isomer are considerably faster than those of the SAP 
isomer.32,41  To attain the highest relaxivities a TSAP isomer should therefore be the preferred 
coordination geometry.  In solution these two coordination isomers can interconvert and a 
mixture of both is usually observed – for GdDOTA itself the SAP isomer is found to be the 
predominant structure (~85%).42  However, by appropriately substituting the ligand framework 
the conformational changes by which the two isomers exchange can be ‘frozen out’, producing a 
chelate that is ‘locked’ into a single coordination isomer.43,44  Careful consideration of the 
stereochemistry enables one coordination isomer to be selected over the other.40  The two 
chelates S-RRR-Ln1 and S-SSS-Ln1are locked into the SAP and TSAP coordination geometries, 
respectively (Figure 1).  Previous studies have demonstrated that the water exchange kinetics of 
S-SSS-Gd1 (τM298≅ 6 ns) are more or less optimal for attaining the highest relaxivities at current 
imaging fields (1.5 T).33  In contrast the water exchange kinetics of S-RRR-Gd1 are considerably 
slower; τM298≅ 70 ns and yet close to the optimal value (~ 20 – 40 ns) predicted for lower 
magnetic field strengths (0.5 T).33 
 
 11 
Figure 1.  The lowest energy conformations of S-RRR-Gd4 (left, orange) and S-SSS-Gd4 (right, 
green) obtained by Simulated Annealing Molecular Dynamics conformational analysis.  These 
structures highlight the different coordination geometries of the two chelates characterized by 
different torsion angles (ϕ) and the position of the hydrophobic substituent – in each case located 
on the corner of the macrocyclic ring in an approximately similar position to that suggested by 
2D NMR experiments.45  Hydrogen atoms have been omitted for clarity. 
Prototypical ‘targeted’ contrast agents derived from these conformationally rigid isomeric 
chelates would allow the effect of varying water exchange kinetics to be probed in the context of 
a targeted imaging approach.  The two chelates were modified to incorporate a hydrophobic 
biphenyl group (Gd4) that could then be used to slow the rate of molecular tumbling of each 
chelate through a binding interaction with either poly-β-cyclodextrin (poly-β-CD) or human 
serum albumin (HSA). 
Synthesis 
The preparation of the isomeric chelates S-RRR-4 and S-SSS-4is shown in Scheme 1.  The 
preparation of S-RRR-1 and S-SSS-1 has been reported previously33 and functionalization of 
these ligands, by conversion to the corresponding isothiocyanate, is facile.46  Catalytic 
hydrogenation using H2 over 10% palladium on carbon afforded the corresponding primary 
amines, 2, in near quantitative conversions.  The primary amines 2were then converted into the 
isothiocyanates3 by reaction with thiophosgene.  Biphasic reaction conditions were employed 
with the thiophosgene dissolved in chloroform and the amine 2 dissolved in water at pH 2.  The 
pH of the reaction is crucial to its success since the stability of isothiocyanates decreases as pH 
rises.  Isothiocyanates react readily with primary amines under mildly basic conditions.  
Accordingly, the isothiocyanates4were dissolved in water, the pH raised to 8 with sodium 
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hydroxide and 4-phenylbenzylamine added with dioxane as a co-solvent to facilitate dissolution.  
After stirring for 24 hours a solution of the appropriate lanthanide chloride in water was added 
and the reaction stirred at room temperature for a further 48 hours.  At periodic intervals the pH 
of the reaction was monitored and maintained above 6 by addition of sodium hydroxide.  The 
Ln3+ chelates of the two biphenyl conjugates S-RRR-4 and S-SSS-4 were isolated and purified by 
preparative HPLC.  Each chelate was isolated as the more favoured ‘corner’ isomer45,47 affording 
the structures shown in Figure 1.  The chelates obtained thusly are isolated as the conjugate acid 
and are poorly soluble in aqueous solution; however, neutralization, by stoichiometric addition of 
NaOH, affords the chelates as their sodium salts, in which form the chelates are freely soluble in 
water. 
 
Scheme 1.  The synthesis of the lanthanide chelates of S-SSS-4, the chelates of S-RRR-4were 
synthesized according to the same synthetic scheme.  Reagents and conditions: i. H2 and 10% Pd 
on C; ii. SCCl2 / CHCl3 / H2O pH 2; iii. 4-phenylbenzylamine / dioxane / H2O pH 8; iv. 
LnCl3.6H2O, pH 6. 
Relaxometric Studies of Biphenyl Conjugates in Solution 
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The relaxivity of a discrete Gd3+ chelate in solution can be determined by measuring the proton 
relaxation rate constant, R1 (= 1/T1) over a range of Gd3+ concentrations.  Because R1 and [Gd3+] 
are linearly related in this case, regression analysis of these data affords the relaxivity, r1, of the 
chelate from the slope of the line.  This standard method of relaxivity determination was applied 
to the chelates S-RRR-Gd4 and S-SSS-Gd4.  Unexpectedly however, neither chelate exhibited a 
linear dependence of R1 on [Gd3+] (Figure 2).  In the concentration range 5 to 1 mM linear 
relationships were observed affording unusually high relaxivity values for each chelate (Table 1 
and supplementary information).  An abrupt change in the slope of the line is then observed 
followed by a second linear region over the concentration range 300 to 10 µM.  In this region the 
slope of the line afforded relaxivity values much closer to those normally expected for low 
molecular weight chelates at 20 MHz and 25 ºC (Table 1).  This behaviour is very similar to that 
observed for other Gd3+ chelate incorporating a long hydrocarbon groups, such as C17-
AAZTA48or a GdDOTA-calix[4]arene derivative.49 As in that case the change in relaxivity can 
be attributed to the formation of micelles, in which the rotation of Gd3+ is slowed, at higher 
concentrations.Gd3+ chelates with large aromatic substituents, such as calix[4]arenes, have 
previously been shown toform micelles.49  The critical micelle concentrations (cmc) of the Gd4 
chelates are somewhat below 0.5 mM, in closer agreement with the value determined for C17-
AAZTA than calix[4]arene substituted DOTA derivatives (Table 1).48,49  The relaxivity values of 
both isomers of Gd4, both above and below the cmc, are somewhat higher than found for either 
the calix[4]arene49derivatives or C17-AAZTA.48 In the former case this is most likely a 
reflection of the slow exchange kinetics exhibited in this system.49  The latter case is noteworthy 
because C17-AAZTA is aq = 2chelate and would therefore be expected to have a somewhat 
higher relaxivity than either Gd4 isomer: both q = 1 chelates.  Given that the water exchange 
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kinetics of C17-AAZTA and S-RRR-Gd4 are comparable this suggests that the primary 
difference between the chelates must arise from more effective slowing of rotation with the 
biphenyl substituent relative to that afforded by the hydrocarbon chain, perhaps through 
continued, weak intermolecular interactions.  Strictly analogous behaviour has also been reported 
and discussed in the cases of functionalized Gd3+ DTPA,50 DOTA,51 and EGTA52 chelates. 
 
Figure 2.  Plots of the paramagnetic 1H relaxation rate (R1p) versus Gd3+ chelate concentration 
for S-RRR-Gd4 (top) and S-SSS-Gd4 (bottom) at 20 MHz and 25 ºC, highlighting the change in 
relaxivity with changing chelate concentration. 
Table 1.  Physicochemical properties of S-RRR-Gd4 and S-SSS-Gd4 obtained from the 
1/T1versus concentration plots in Figure 2. 
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Chelate cmca / mM 
r1 / mM-1s-1 
below cmc above cmc 
S-RRR-Gd4 0.42 ± 0.02 10.7 40.8 
S-SSS-Gd4 0.29 ± 0.02 9.0 28.2 
a) cmc = critical micelle concentration 
 
The formation of micelles can unambiguously be demonstrated by recording the nuclear 
magnetic relaxation dispersion (NMRD) profiles of each chelate at concentrations above and 
below the cmc.  The NMRD profiles at low concentrations (0.2 mM) of S-RRR-Gd4 and S-SSS-
Gd4 are characteristic of small molecule Gd3+ chelates in which relaxivity is limited by τR 
(Figure 3);10 the relaxivity is higher at very low fields, there is a dispersion around 1 MHz 
followed by a more gradual decrease in relaxivity at higher fields.  However, the profiles have 
two points of interest.  Firstly, the relaxivity of the agents is quite high for discrete chelates, and 
this can be attributed to either the increase in hydrodynamic volume associated with the inclusion 
of a bulky biphenyl substituent in the structure, or weak intermolecular associations – reducing 
the rate of molecular tumbling (longer τR).  Secondly, and perhaps more significantly, the two 
curves are almost identical across the entire frequency range of the profile, but offset from one 
another by about 1.5 mM-1s-1.  This same observation can be made retrospectively for the 
previously reported NMRD profiles of S-RRR-Gd1 and S-SSS-Gd1.33  The fact that these profiles 
are almost superimposable but offset in this way, tells us that theprimary difference between the 
two chelates is not a frequency dependent parameter such as τM, τR, T1e or T2e.There is a very 
slight additional difference in the dispersions (0.5 to 5 MHz) of the two profiles that suggests a 
small difference in one of these field-dependent parameters.The primary difference between the 
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two chelatesmust be a parameter with which relaxivity scales directly: in other words either q or 
rGdH. 
Hydration in Ln3+ chelates has been something a contentious matter for over a decade now.  
The disagreements have largely arisen from differing opinions of how to describe differences in 
hydration between chelates, the debate may appear largely one of semantics but it arises because 
of the difficulty the scientist faces in describing hydration.  Both q and rGdH are parametric 
descriptors of hydration and the problem is how to define each for a chelate in aqueous solution, 
and therefore in exchange.  It has been possible to account for some of the observed coordination 
chemistry of the later lanthanides (Ho3+→ Lu3+)by invokinga TSAP coordination isomer that is 
entirely dehydrated(q = 0) in solution.42,53-55 However, there is no published evidence for the 
existence of a discrete, dehydrated TSAP isomer of DOTA-type chelates of lanthanides from the 
middle of the series (Eu3+ and Gd3+). In systems where changes in hydration leads to changes in 
the coordination geometry the non-degenerate 5D0→7F0 transition of the Eu3+ ion can be used 
probe hydration equilibria.56  The Eu3+ coordination geometry in DOTA-type chelates changes 
only subtly with changing hydration54and the high resolution emission spectra (supplementary 
information, S1) of both S-RRR-Eu4 and S-SSS-Eu4 each exhibit a single line for this transition 
at about 578 nm.  This may reflect a single hydration species for both chelates (even though the 
S-SSS-Eu1isq = 0.74 as determined by Horrocks’ method)30 or it may be that changes in 
hydration do not afford sufficient changes in the energy of this transition to resolve the different 
hydration species.As discussed previously there exists no good method for accurately 
determining rGdHin solution.  Although Caravan and co-workers have proposed ENDOR as a 
means of probing this parameter,34 it is important to note that those experiments were performed 
at very low temperatures on static chelates in frozen glasses, a condition that does not in any way 
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resemble the situation of a chelate undergoing exchange in solution.Herein lies the quandary; the 
hydration states of S-RRR-Eu1 and S-SSS-Eu1 are very different when determined by Horrocks’ 
method – q =0.97 and q = 0.74, respectively – how should this difference be interpreted?  Insight 
can be gained from two very different pioneering studies.  The work of Parker and co-workers30 
has unambiguously shown that Horrocks’ method does not provide simply the hydration number, 
in fact it provides both the hydration number and the position of those water molecules in a 
single parameter: i.e.Horrocks’ hydration state describes both q and rEuHinone parameter.  In his 
pioneering relaxometric studies on paramagnetic metal ions Bertini, encountered the same 
problem, and recognizing what Parker would later demonstrate, he used a single parameter to 
describe the hydration state of the metal ion: q/rMH6.57,58The hydration states of the two Eu1 
chelates determined by Horrocks’ method, unambiguously demonstrate a difference in the 
hydration states of the two chelates.33  This difference can be represented either as a difference in 
q, a difference in rGdH, or more properly as a difference in q/r6.  For the purposes of the data 
analyses performed herein we have employed values of q/rGdH6 = 1372nm-6and1127 nm-6 for S-
RRR-Gd4 and S-SSS-Gd4, respectively.  For reasons of simplicity and familiarity these values 
can be considered to represent two q = 1 chelates in whichrGdHincreases by 0.1 Å or 3.3% (from 
3.0Å to 3.1Å)on passing from S-RRR-Gd4 to S-SSS-Gd4.Throughout this article we will employ 
this description of hydration; however, the reader must recognize two important points: 1) 
although we will describe q as fixed with only rGdH in variance, in truth either or both hydration 
parameters may be different between the two chelates; 2) the values of q/rGdH6 for each chelate 
are not known, the values, and the difference between them, that are employed hereinare more 
illustrativethan precise representations of the hydration in these chelates.  However, given the 
previously noted differences of rLnH (2.8 % in the crystal, 4.5 % in solution)31-33 between SAP 
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and TSAP isomers the difference seems reasonable and the values of rGdH lie within the range of 
commonly used values for this type of analysis.  Any errors in the values employedwill be 
reflected in deviations in the values of τR from the real values. Muller and co-workers have 
shown that when fitting NMRD profiles variance in the value of rGdH, usually fixed, causes a 
variance in the obtained value of τR.28  Thus, unless τR is independently determined and fixed 
during fitting, there is some flexibility to the value of rGdH employed provided that the effect on 
the value of τR is appreciated.  This flexibility may explain why it has not previously been found 
necessary to consider the effect of variation in hydration (q/rGdH6) between chelates when 
undertaking these fittings. 
 
Figure 3.  The 1H 1/T1 NMRD profiles of S-RRR-Gd4 (SAP, open diamonds) and S-SSS-Gd4 
(TSAP, closed circles) recorded at 0.2 mM and 25 °C.  Dashed lines represent the calculated 
outer-sphere contribution to relaxivities. 
Taking this approach to hydration both NMRD profiles fit well to theory. In all NMRD fittings 
herein the water exchange parameterτM has been taken from studies on the corresponding isomer 
of Gd1, it is not possible to measure the water exchange kinetics of Gd4 chelates directly by 17O 
NMR methods due to solubility constraints.  The assumption was madethat the peripheral 
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incorporation of a biphenyl group has no significanteffect upon the water exchange kinetics of 
the chelate. The τM value for S-RRR-Gd4was fixed at the value determined for the corresponding 
isomer of Gd1.33A variation of this τM value by ± 30 ns resulted in a relaxivity change of less 
than 0.3 mM-1s-1 at all fields.  In the case of S-SSS-Gd4 fitting was found to be largely insensitive 
to small changes in τM over a range 5 – 10 ns and data were fitted using a τM value, 8 ns, that 
best fits the data.  The values of τR obtained from fitting the low concentration NMRD profiles of 
both chelates are somewhat longer than expected for relatively small chelates (Table 2).  This 
may reflect an underestimation of rGdH on our part.  Alternatively, these longer than expected 
values could reflect an increased level of intermolecular π-π interaction (without forming 
micelles) that will tend to slow rotation and increase relaxivity as discussed earlier.  Effects of 
this type have been observed by Merbach and Helm for other chelates including aromatic 
groups.59,60The similarity in the values of τRis expected since the two chelates are isomeric.The 
parameters ∆2 and τV are reflective of the zero-field splitting and its transient modulation, 
respectively, which govern the electron spin relaxation time constants of the chelate. In both 
isomers of Gd4 the value of τV is somewhat different (larger) than is usually obtained in this type 
of exercise for these types of chelate.  Crucially both isomers have very similar electron spin 
relaxation characteristics, a feature that has been previously established through EPR analysis of 
analogous chelates to the two isomers of the Gd1.24  Given that the relationship between electron 
spin relaxation and coordination chemistry is poorly understood it is difficult to point to a direct 
physical reason as to why τV is longer than might be expected. However, it is worth noting that a 
marked lengthening of this parameter is very often observed in macromolecular systems.10,61That 
the difference between the two NMRD profiles arises primarily from difference in hydration 
state between the two chelates is shown by simulating anNMRD profile using the same 
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parameters obtained from the fitting of the profile of S-RRR-Gd4but extendingrGdHfrom 3.0 to 
3.1 Å.  This affords a curve that almost exactly fits the experimental data obtained for S-SSS-Gd4 
(supplementary information S2), indicating that almost the entire difference between the two 
profiles is accounted for in the change in rGdH. 
 
Table 2.  Best-fit parametersa,b of the NMRD profiles of S-RRR-Gd4 and S-SSS-Gd4 in Figures 3 
and 4. 
 [Gd3+] = 0.20 mM [Gd3+] = 3.98 mM 
 S-RRR-Gd4 S-SSS-Gd4 S-RRR-Gd4 S-SSS-Gd4 
rGd-H / Åb 3.0 3.1 3.0 3.1 
τM / nsb 70 8 70 8 
∆2 / 1019 s-1 0.62 0.61 2.4 2.6 
τV / ps 42 45 29 20 
τR / ps 229 220 - - 
τg / ns - - 3.84 3.38 
τl / ns - - 0.45 0.43 
S2 - - 0.34 0.33 
a) Fitting used a = 3.8 Å, 298D = 2.24×10-5 cm2 s-1and q= 1.  b)parameter fixed during fitting. 
 
The NMRD profiles of the two isomers of Gd4 recorded at a 3.98 mM, above the cmc, (Figure 
4) are characteristic of more slowly tumbling chelates: a classical high field ‘hump’ is observed 
in each case indicating the formation of a slowly rotating species, micelles, at higher 
concentrations.  It should be noted that NMRD profiles for slowly rotating systems are shown 
and fitted herein only in the high field region because of the known limitations of SBM theory in 
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the slowly rotating regime that render it unable to completely account for the behaviour of more 
slowly rotating chelates at very low magnetic field strengths.62  These profiles are notable 
because the high field relaxivity enhancement arising when molecular tumbling is slow (longer 
τR) is greater for S-RRR-Gd4, the isomer (SAP) with the more slowly exchanging water 
molecule. This is in direct contrast to the general expectation that more rapid water exchange 
kinetics(up to an optimal value of about 6 ns at 1.5 T)7,33 will afford higher relaxivities. Fitting 
these profiles to SBM theory, incorporating the Lipari-Szabo model,63,64 affords valuable 
information about the tumbling dynamics of each chelate in the micelle. The advantage of the 
Lipari-Szabo model is that it separates the local and global tumbling motions of the chelate, 
allowing the effect of local molecular motion on relaxivity to be considered.  Fitting was 
undertaken with the aforementioned difference of 0.1 Å in the values of rGdH used for the two 
isomeric chelates.  The fits afforded comparable values of τg and τl; the global and local 
molecular tumbling correlation times, respectively.  These results indicate that the micelles 
formed by each isomer of Gd4 are of comparable size and that within each the Gd3+ chelate has 
broadly similar freedom of rotation.  The difference in relaxivity of the isomers of Gd4 in 
micelles can only partially be the result of differences in molecular rotation between the two 
systems. The major difference between the two profiles again stems from the longer rGdH value 
found for S-SSS-Gd4. This is demonstrated by a simulation of the NMRD profile of S-SSS-Gd4 
using τM = 70 ns and rGdH = 3.0 Å – the values applied to the fitting of S-RRR-Gd4 – but keeping 
all other parameters the same as in the fit (dashed line, Figure 4).  This simulation accounts for 
the majority of the relaxivity enhancement observed for S-RRR-Gd4 and indicates that the 
primary limitation to enhancing relaxivity at high fields for S-SSS-Gd4 is a combination of the 
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longer rGdH value observed for this chelate and a value of τM that is rather too short to optimize 
relaxivity at 20 MHz. 
 
Figure 4.  The high field region of the 1H 1/T1 NMRD profiles of S-RRR-Gd4 (SAP, open 
diamonds) and S-SSS-Gd4 (TSAP, closed circles) recorded at 3.98 mM and 25 °C.  Solid lines 
represent fits to the data, the dashed line is a simulated profile taking the fitting parameters from 
the profile ofS-RRR-Gd4but applying the water exchange parameters τM and rGdHfrom theS-SSS-
Gd4 profile.  Profiles including the low field region are provided in the supplementary 
information (S3, S5& S7). 
As previously noted the τM value of S-SSS-Gd4, at 8 ns, is somewhat shorter than optimal at 20 
MHz, under the traditional SBM paradigm.10,33  This is reflected in a shift of the maxima of the 
two relaxivity ‘humps’ in the NMRD profiles shown in Figure 4. The more rapidly exchanging 
S-SSS-Gd4 exhibits a ‘hump’ maximum that is at 10 to 20 MHz higher field than the more 
slowly exchanging S-RRR-Gd4, consistent with expectation based on the different water 
exchange kinetics of the two isomers. However, it is important to note that even at the higher 
fields where the exchange rate of S-SSS-Gd4would be considered optimal the relaxivity of S-
RRR-Gd4 remains higher and this must be a direct result of the increase in rGdH.10,33 
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Interactions of biphenyl conjugates with poly-β-cyclodextrin 
Hydrophobic groups such as the aromatic substituent of Gd4are known to form inclusion 
compounds with β-cyclodextrin (β-CD).  Cyclodextrins themselves are not sufficiently large to 
slow rotation to the extent that substantial gains in relaxivity can be realized, but polymers of 
cyclodextrins are large enough and have previously been used to slow molecular tumbling and 
increase relaxivity.65-67  Poly-β-cyclodextrin (poly-β-CD) contains an average of 10 - 11 β-CD 
units, each of which can bind and slow the tumbling of Gd4.  The advantage of this approach is 
that, unlike the serum albumin binding described below, poly-β-CD affords only approximately 
equivalent binding sites and will slow the rotation of each chelate it binds approximately 
equivalently.  In consequence, the binding of Gd4 to poly-β-CD conforms, to a first 
approximation, to a simple 1:1 binding model.  Titrating a dilute solution of Gd4 with poly-β-CD 
and measuring the change in water proton relaxation rate affords typical binding curves for both 
isomers of Gd4 (Figure 5).  The increase in water proton relaxation rate as Gd4 is added to poly-
β-CD is a clear indication of a reduction in the rate of molecular tumbling of the Gd3+ chelates 
(longer τR) as the chelates bind to the polymer. The data were fitted to a simple model that 
considers the presence of 11 equivalent and independent binding sites, affording association 
constants and bound relaxivities (r1bound) for the two isomeric chelates (Table 3). 
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Figure 5.  The effect of poly-β-CD on the longitudinal relaxation rate (20 MHz, 25 ˚C) of dilute 
solutions (0.17 mM) of S-RRR-Gd4 (SAP, open diamonds) and S-SSS-Gd4 (TSAP, closed 
circles). 
Table 3.  Fitting parameters for the binding of the two isomers of Gd4 to poly-β-CD 
 Ka / M-1 r1bound / mM-1s-1a 
S-RRR-Gd4 0.51 ± 0.05 × 103 46 ± 0.7 
S-SSS-Gd4 0.87 ± 0.07 × 103 30 ± 0.5 
a) Measured at 20 MHz and 25 ˚C. 
 
The association constants determined in this way (Table 3) are probably a good reflection of 
the strength of the interaction between each isomer of Gd4 and a β-CD unit.  Although these 
values are an average over all β-CD of the polymer there is no reason to suppose that the binding 
of one chelate by poly-β-CD will substantially change the binding of any of the others and each 
binding site must be very similar, if subtly different. The binding of S-SSS-Gd4 to β-CD is 
somewhat stronger than that of S-RRR-Gd4 even though the same group is responsible for 
binding in each case. Since these are interactions between chiral host and chiral guest in each 
 25 
case, differences in the binding of the two isomers were expected.  The results of molecular 
modelling studies (below) further highlight how these differences in interaction are likely to 
occur. Unlike Ka, the relaxivity of Gd4 bound to poly-β-CD is expected to vary somewhat 
depending on the location of the β-CD unit in the polymer – chelates bound closer to the middle 
of the molecular assembly could reasonably be assumed to have less (or at least slower) motion 
of rotation than those closer to the ends.  In this light it is important to treat r1bound values as 
averaged values rather than absolute values for a discrete chelate.  Nonetheless, this exercise is 
highly instructive; the bound relaxivity (Table 3) of the more rapidly exchanging TSAP isomer 
again has lower value than the more slowly exchanging SAP isomer when molecular tumbling is 
slowed. 
NMRD profiles of the two isomers of Gd4 were recorded under conditions that ensured > 96 
% of the chelate was bound to poly-β-CD (Figure 6). Again only the high field region of the 
profiles are shown and fitted.  Notably the two profiles closely resemble those obtained for the 
chelates in micelles.  Fitting the profiles to SBM theory (including the Lipari-Szabo model) 
affords similar rotational correlation times, τg and τl, for the two isomers of Gd4 bound to poly-
β-CD (Table 4) indicating that differences in molecular tumbling between the two isomers are 
not the primary cause of the difference in relaxivity.  Yet again it is found that the critical impact 
of the longer rGdH value of S-SSS-Gd4 is the primary cause of the lower relaxivity observed for 
the more rapidly exchange TSAP isomer.  A profile simulated with fitting parameters for S-SSS-
Gd4, but using the water exchange parameters for S-RRR-Gd4, accounts for all of the difference 
between the profiles at the high and low field regions of the relaxivity ‘hump’ and most (about 
80%) of the ‘hump’ around 20 MHz (dashed line, Figure 6).  The remaining differences in 
relaxivity may be attributed to the small differences that exist between the local rotations (τl) of 
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the two chelates when bound to poly-β-CD. The relaxivity maximum observed for each chelate 
exhibits the same field dependence as observed in the micelle system – the more rapidly 
exchanging isomer peaking at higher field – consistent with expectation. 
 
Figure 6.  The 1H 1/T1 NMRD profiles of S-RRR-Gd4 (red diamonds) and S-SSS-Gd4 (blue 
circles) recorded at [Gd3+] = 0.17 mM in the presence of 6 mM poly-β-CD at 25 ˚C. 
Table 4.  Best-fit parameters of the NMRD profiles (25 °C) of the inclusion complexes of the 
two isomers of Gd4 with poly-β-CD.a 
 S-RRR-Gd4 S-SSS-Gd4 
rGd-H / Åb 3.0 3.1 
τM / nsb 70 8 
∆2 / 1018 s-1 2.8 3.7 
τV / ps 18 12 
τg / ns 4.2 3.6 
τl / ns 0.40 0.45 
S2 0.45 0.42 
a) Fitting used a = 3.8 Å, 298D = 2.2×10-5 cm2 s-1and q= 1.  b)parameter fixed during fitting. 
 
 27 
Interactions of biphenyl conjugates with Human Serum Albumin 
Titrating human serum albumin (HSA) into dilute solutions of Gd4 below the cmc clearly 
demonstrates the relaxivity enhancement afforded by the interaction of the Gd3+ chelate with the 
protein (Figure 7).  As the amount of HSA present increase, the relaxivity of each chelate 
increases as the chelate binds to the protein and molecular tumbling is slowed.  However, unlike 
poly-β-CD with its approximately equivalent binding sites, HSA has multiple, very different 
hydrophobic binding sites and is capable of binding a large number of hydrophobic molecules 
simultaneously.  Because chelate binding in proteins such as HSA is allosteric, the binding of 
Gd4 at any given site alters the chelate-proteininteraction at all other binding sites.  As a 
consequence, fitting this type of titration data does not provide information with true physical 
meaning about the agent, its binding or relaxivity.  A binding model incorporating 3 equivalent 
binding sites on the protein describes the data for each chelate quite well and allows a qualitative 
assessment of the titration data in Table 5.  From the inflection of the binding curve which occurs 
significantly before a 1:1 stoichiometry it is clear that both chelates bind reasonably avidly to 
more than one site on the protein, justifying the use a 3:1 binding model.  The overall binding 
affinity of S-RRR-Gd4 appears to be higher than that of S-SSS-Gd4.  Furthermore, the effect of 
the longer rGdH value for S-SSS-Gd4 is again evident as its relaxivity is evidently lower than that 
of S-RRR-Gd4. 
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Figure 7.  Relaxometric titrations HSA of into 100 µM solutions of S-RRR-Gd4 (SAP, open 
diamonds) and S-SSS-Gd4 (TSAP, closed circles) at 20 MHz and 25 ˚C.  A qualitative data fit is 
provided (Table 5) using a binding model with 3 equivalent binding sites. 
Table 5.  Binding parameters obtained from the qualitative fit of the relaxometric titration of 
HSA with S-RRR-Gd4 and S-SSS-Gd4 using a 3:1 binding model with equivalent binding sites. 
 KHSA-Gd4 (× 103 M-1)a r1bound (mM-1s-1)a 
S-RRR-Gd4 71.3±12.4 46.8±0.9 
S-SSS-Gd4 49.7±7.9 37.6±0.6 
a) apparent values (see text) 
Relaxometric titrations cannot discriminate between chelates bound to different sites on the 
protein and it is highly unlikely that either chelate is able to find three equivalent sites at which 
to bind.  To probe the binding interactions in more depth site specific binding assays are 
required. The work of Sudlow and co-workers68,69 has provided a great deal of information about 
the binding interactions of HSA as well as methods for probing these interactions.  Caravan and 
co-workers employed those methods to probe the interactions of the clinical blood pool agent 
MS-325.70 Given the well-developed nature of this experimental protocol identical techniques 
were used to probe the binding of each isomer of Gd4 to HSA.  A fluorescent probe specific for a 
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particular biding site on HSA was added to a solution of defatted HSA and its displacement by 
Gd4 followed by fluorescence.  Warfarin is a probe that is known to selectively bind in what 
Sudlow designated drug binding site I.68  When either isomer of Gd4 was titrated into the 
solution no displacement of warfarin from HSA was observed (Supplementary Information, S4).  
This appears to indicate that there is no binding of either isomer at this site; however, drug 
binding site I is a very large binding domain and three distinct subdomains: a, b and c; have been 
noted within drug binding site I.71  Warfarin binds in subdomain Ia which is the subdomain 
located closest to the mouth of the binding pocket and between subdomains Ib and Ic.  When 
bound, warfarin is known to extend partially into both subdomains Ib and Ic, and therefore 
binding of Gd4 in either subdomain Ib or Ic was expected to lead to at least partial displacement 
of warfarin from drug binding site I.  In light of the results from the relaxometric titrations the 
possibility that drug binding site I is able to accommodate Gd4 and warfarin simultaneously, 
without displacement of warfarin, cannot be excluded.  Indeed the results of molecular modelling 
studies (below) suggest that from an energetic perspective binding of the chelates in this site 
remains a possibility.  In contrast dansylsarcosine binds selectively in what Sudlow designated 
drug binding site II.68  Gd3+ chelates, including the clinical HSA binders MS-325 and 
GdBOPTA, are often found to bind in drug binding site II.  Perhaps not unexpectedly then 
addition of either isomer of Gd4 resulted in displacement of the dansylsarcosine causing a 
decrease in emission intensity (Supplementary Information, S4).  Following the methods of 
Caravan and co-workers, inhibition constants for the fluorescent probe at drug binding site II can 
be determined for each isomer from which the strength of each association can be calculated 
(Table 6).  The association constants determined in this way are of a similar magnitude to that 
observed for MS-325.  Notably the two isomers have quite different association constants for 
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binding at drug binding site II but these results are in contradiction to those obtained from the 
relaxometric titration (Figure 7).  The binding of S-RRR-Gd4, globally stronger from the 
relaxometric titration, is the weaker of the two isomers at drug binding site II.  Two factors could 
contribute to this difference.  Firstly, S-RRR-Gd4 could either be binding more strongly to other 
sites or binding to more sites on HSA – the results of molecular modelling studies (below) 
suggest that even drug binding site I could be occupied by this chelate.  Secondly, the apparent 
r1bound value determined from the relaxometric titration (Table 5), as noted previously, has no 
physical relation to the behavior of any single chelate molecule.  This value is a weighted 
average over chelate bound to all sites, none of which are expected to have identical relaxivities, 
and the model allows for only three bound chelates when in fact there could be many more.  As a 
result, this parameter may easily be an underestimate, and if this were indeed the case then the 
value of the association constants determined from the fitting would tend to be overestimated. 
 
Table 6.  The association constants of the two isomeric biphenyl conjugates Gd4 in the two drug 
binding sites of HSA determined at 25 ˚C.  
Fluorescent probe Binding Site 
KHSA-Gd4 / M-1 
S-RRR-Gd4 S-SSS-Gd4 MS-325a 
Warfarin I n.d. n.d. n.d. 
Dansylsarcosine II 9.2 ± 0.5× 10-3 22.1 ± 1.9 × 10-3 11.8 × 10-3 
a) taken from reference 70 and determined at 37 ˚C;  n.d. indicates that no displacement of the 
fluorescent probe was detected. 
 
NMRD profiles were collected for both isomers under conditions designed to maximize the 
amount of Gd4 bound to HSA (Figure 8).  Conditions were chosen under which >99% of each 
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isomer of Gd4 is estimated to be globally bound to HSA, respectively (80 and 85 % bound to site 
II, respectively, on the basis of the displacement experiments).  Given the distribution of 
environments in which Gd4 could be found in these systems any NMRD fitting is without 
meaning and thus none was attempted.  The same overall pattern is observed as for the other 
slowly tumbling systems studied herein.  High field relaxivity ‘humps’ are again observed for 
both chelates but the ‘hump’ maximum observed for S-RRR-Gd4 is significantly higher than that 
of S-SSS-Gd4.  This can again be attributed to the difference metal-water distance, rGdH, between 
the two isomeric chelates.  On the higher field edge of the ‘hump’ the relaxivity of both agents 
falls off quickly, consistent with theory.  It is evident that the relaxivity of S-RRR-Gd4 falls off 
more quickly than that of S-SSS-Gd4 until, at around 40 MHz, it falls below that of S-SSS-Gd4.  
This observation is expected on the basis of the previously determined water exchange rates of 
each chelate; that determined for S-SSS-Gd4 being more suitable for achieving higher relaxivities 
at higher fields, according to the traditional SBM paradigm.10,33 
 
Figure 8.  The 1H 1/T1 NMRD profiles of solutions of the two isomers of Gd4 (0.15 mM) and 
HSA (1.8 mM): S-RRR-Gd4 (open symbols); and S-SSS-Gd4 (closed symbols) recorded at 25 ˚C. 
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Variable temperature relaxometry and molecular modelling studies 
One key assumption has been made in the analysis of all the relaxivity measurements herein: 
the water exchange kinetics of both chelates remains virtuallyunaffected by the interactions that 
slow the global rate of molecular tumbling.  This is a point of particular relevance when 
considering the agents bound to HSA as it has previously been reported that the interaction of a 
chelate with the protein can affect its water exchange kinetics.70,72-74  The water exchange 
kinetics of Gd3+ chelates are accurately determined by measuring the effect of changing 
temperature on the 17O transverse relaxation rate of water in a solution of the chelate.75,76  The 
water exchange kinetics of the two isomeric Gd1 chelates were determined using this method.33  
The limitation of this technique is that it requires relatively high concentrations of Gd3+ 
(typically 10-2 M), much higher than the limits of solubility of HSA or poly-β-CD. Samples 
cannot then be prepared in which sufficient chelate is present in solution under conditions where 
the majority of the chelate is bound to the macromolecule.  The water exchange kinetics of the 
bound chelate cannot therefore be determined in this manner.  Caravan and co-workers proposed 
a method by which absolute quantification of water exchange kinetics could be achieved from 
variable temperature 1H relaxation measurements at much lower chelate concentrations using the 
corresponding Dy3+ chelate.72  It is generally considered that Ln3+ ions may be interchanged to 
afford differing types of information that build up a picture of the overall coordination chemistry 
– as noted earlier where the Eu3+ chelate was studied to probe hydration equilibria.  However, in 
our case there are concerns that switching to a heavier Ln3+ ion (rather than the lighter Eu3+ ion) 
will bring the TSAP isomer closer to a tipping point at which a proportion of the chelate is 
dehydrated in solution (q = 0). Dy3+ is adjacent to Ho3+ in the lanthanide series and from recent 
crystallographic data on a TSAP Ho3+ chelate it is evident that the hydration equilibrium of a 
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TSAP Ho3+ chelate in solution is complex indeed.77  The extent to which the hydration and 
exchange kinetics of a TSAP Dy3+ chelate can be said to reflect those of a TSAP Gd3+, with its 
much simpler hydration behaviour, is highly questionable.  For this reason we took two different 
approaches to assess the likelihood of changes in water exchange kinetics as the rate of 
molecular tumbling is slowed. 
 Firstly, molecular models were used to examine the orientation of the chelates when 
bound to the macromolecules HSA and poly-β-CD.  The results of modelling the interactions 
between Gd4 and β-CD suggest very similar interactions for both isomeric chelates (interaction 
energies of -24.4 ±1.4 kcal/mol and -25.7 ± 0.8 kcal/mol for the S-RRR-Gd4 and S-SSS-Gd4, 
respectively), consistent with the experimentally determined association constants.  The 
orientation of each isomeric chelate when bound to a β-CD unit (Figure 9) may help explain the 
observed differences in the Ka for the two chelates.  From the molecular models it is clear that in 
each case the biphenyl group extends right through the cyclodextrin binding pocket and it is the 
para- substituted phenyl and thiourea group that are held in the binding cavity.  Binding is thus 
the result of hydrophobic interactions between the phenyl group and the inner surface of the 
cavity and hydrogen bonding interactions between the thiourea group and the primary hydroxyl 
groups on the narrow rim.  This binding mode brings the chiral chelate in close proximity to the 
wider rim of the β-CD cavity. β-CD interacts stereoselectively with chiral compounds78 and here 
the secondary hydroxyl groups of the wider rim will interact differently with the chelates’ 
pendant arms depending upon their orientation (either Λ or ∆).  In each case the hydrophobic 
substituent is located on the corner of the macrocycle (Figure 1) which orients the water 
coordination site such that it will rotate pointing up and away from the β-CD unit, into the bulk 
water. It would be expected that such an orientation would minimize interference in the water 
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exchange process of both isomers of Gd4 when bound to poly-β-CD. We may reasonably 
assume that binding of Gd4 to β-CD does not significantly influence the rate of water exchange 
in either chelate – any influence from this binding can reasonably be assumed to be very similar 
for each isomeric chelate.  
 
Figure 9. Results of the calculated docking procedure applied to β-CD and S-RRR-Gd4 (orange); 
and β-CD and S-SSS-Gd4 (green).  The β-CD surface is depicted with a red semi-transparent 
Gauss-Connolly surface.  Both isomers place the para-phenyl group inside the hydrophobic 
cavity, with the thiourea moiety forming hydrogen bonding interactions with the primary 
hydroxyl groups of the narrow rim. 
Although experimentally no displacement of warfarin was observed, molecular modelling 
studies suggest that both isomers of Gd4 are capable of binding in drug binding site I (Figure 
10).  They would need to be capable of doing so without displacing warfarin and it is possible to 
model the docking of both isomers Gd4 in such a way as to accommodate both Gd4 and warfarin 
in the binding pocket.  This is possibility arises only because the binding pocket of drug binding 
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site I is so large that accommodation of the Gd3+ chelate simultaneously with the fluorescent 
probe is possible.52  Despite the size of this binding pocket, docking calculations show the 
biphenyl groups held in the binding pocket with the chelates held at some distance away from the 
mouth of the pocket by the para-phenyl linker.  This suggests a considerable degree of freedom 
of motion on the part of the chelate end of the molecule.  Although the calculated docking modes 
orient the water binding face of the isomeric chelates in different directions relative to the protein 
surface, they are both pointing essentially outward towards the bulk water. It is important to bear 
in mind that these are single low energy minima of the chelate positions and are not a reflection 
of the time-averaged orientation of the water binding face. Given the apparent freedom of motion 
of each chelate when bound to HSA it seems unlikely that the exchangeable water molecule of 
either chelate is constrained to face towards the protein surface which could result in an apparent 
deceleration of water exchange. 
Both isomers of Gd4are experimentally found to bind to drug binding site II of HSA (Table 6). 
Docking calculations position S-SSS-Gd4 more deeply in the pocket than S-RRR-Gd4, this 
permits the thiourea to engage the side chain of Ser489 in hydrogen bonding interactions (Figure 
10).  Such a difference in binding mode may have a significant impact on the freedom of local 
rotation of the two chelates.  The chelate of S-SSS-Gd4 will be held more closely to the surface 
of the protein which may reasonably be presumed to reduce local rotation of the chelate. This 
would tend to increase relaxivity.  However, the difference in binding mode provides no reason 
to suppose that the water exchange rate of either chelate would be affected by this binding.  Both 
chelates will rotate locally around a point of attachment (the corner of the macrocycle) which 
would seem to maintain the water coordination site of each isomer pointing away from the 
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protein surface and into the bulk.  These results may account for the stronger binding interactions 
observed for the S-SSS-Gd4. 
 
Figure 10.Calculated docking of S-RRR-Gd4 (orange); and β-CD and S-SSS-Gd4 (green) to 
HSA: a) to drug binding site I; b) to drug binding site II.  The hydrogen bonding interaction 
between S-SSS-Gd4 with Ser489 (drug binding site II) is highlighted in purple.  Hydrogen atoms 
have been omitted for clarity. 
In a qualitative sensethe accuracy of the binding predictions that come out of these modelling 
exercises can be tested through variable temperature 1H relaxation measurements. Since a 
number of parameters that are temperature dependent controls relaxivity, the temperature profile 
of relaxivity can be very informative. This is of particular relevance here since τM has a non-
negligible effect upon the characteristic correlation time τC (equation 3) when τR is long, i.e. in a 
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slowly rotating system.  Furthermore, τM is a primary determinant of the effectiveness of the 
transfer of the paramagnetic effect to the bulk (equation 1). 
From the Solomon-Bloembergen-Morgan equations (eqns 1-3) two limiting cases for inner-
sphere relaxivity (r1is) may be defined: 
The fast exchange regime,  τM<T1M.  For low molecular weight Gd3+ chelates this condition 
typically occurs when τM298< 100 – 200 ns.   
The slow/intermediate regime,  τM≥T1M.  In this regime the rate of water exchange is so slow 
that the condition τM>T1M occurs over an extended temperatures range. 
In the fast exchange regimeT1M is the primary determinant of inner-sphere relaxivity.  At low 
temperatures τR and T1,2e, and therefore τC, are long.  The result is that T1M shortens with 
decreasing temperature causing relaxivity to rise with decreasing temperature. In slowly 
tumbling macromolecular systems the values of T1M are also shorter and the fast exchange 
regime is not reached until τM298< 30 ns.  In the slow/intermediate exchange regime inner-sphere 
relaxivity decreases with decreasing temperature and eventually tends towards zero, following 
the increase of the water exchange lifetime. 
The temperature relaxivity profiles of each isomer of Gd4were recorded under three of the 
molecular tumbling regimes described herein: as discrete chelates below the cmc; when bound to 
poly-β-CD; and when bound to HSA (Figure 11).  The temperature response of the relaxivity of 
the discrete chelates (Figure 11a) reflects the known difference in water exchange kinetics 
between the two isomeric chelates.  At room temperature and above both chelates are in fast-
exchange regime and their relaxivity decreases exponentially with temperature.  As temperature 
dips below about 15 ˚C the behavior of the two chelates begins to deviate: while S-SSS-Gd4 
remains in the fast exchange regime, for S-RRR-Gd4 the value of τM becomes so long as the 
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temperature continues to drop that the chelate drops out of the fast exchange regime and 
relaxivity begins to flatten out, eventually dropping below that of S-SSS-Gd4.These temperature 
profiles can be fitted in terms of the parameters ∆Hi# (i = M, V, R, D)using the best-fit 
parameters from Table 2, and assuming an Eyring-type behaviour for the parameters τR, τM, τV 
and D (the relative diffusion coefficient of solvent and Gd3+ chelate).  This procedure affords 
excellent fits that strongly support the previously determined values of the τM values for the two 
Gd4 isomers.33 
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Figure 11.  Variation in the paramagnetic 1H relaxivity of S-RRR-Gd4 (open symbols) and S-
SSS-Gd4 (closed circles) at 20 MHz: a) as discrete chelates in solution below the cmc; b) bound 
to poly β-CD; and c) bound to HSA at the same concentrations as in Figure 8.  Solid lines are a) 
fits to the data and b) and c) a guide to the eyes only. 
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In the two slowly tumbling systems (Figure 11b and c) the relaxivity of S-SSS-Gd4 exhibits an 
increase in relaxivity with decreasing temperature similar to that observed for the discrete 
chelates; indicating that the chelate remains in the fast exchange regime throughout.  In contrast, 
the relaxivity of S-RRR-Gd4 decreases with decreasing temperatures indicating that the water 
exchange is slower.  The decrease in T1M arising from slower molecular tumbling drives the 
chelate into a slow/intermediate exchange regime.  Notably, in each profile there is a single 
temperature at which the relaxivity of the two isomers are equal and this temperature increases as 
the system rotated more slowly, reflecting the effect of decreasing T1M on S-RRR-Gd4 in the 
slow/intermediate exchange regime.  What these data show is that the relative rates of water 
exchange of the two isomers remain consistent across the systems studied herein: S-RRR-Gd4 is 
a more slowly (but still rapidly) exchanging chelate and S-SSS-Gd4 a more rapidly exchanging 
chelate in all these systems and binding of these agents to either poly-β-CD and HSA does not 
affect this situation. 
 
Conclusions 
Conventional wisdom in the field of contrast agent development has held that in order to 
maximize relaxivity it is necessary to make two modifications to the low molecular weight Gd3+ 
chelate currently employed in this role. First, the chelate must be prevented from tumbling 
rapidly in solution, such that τR> 1 ns or so.  Secondly, water exchange must be accelerated to 
some optimal value, such that τM< 20 ns.  While it is undeniably the case that slow molecular 
tumbling and fast water exchange hold the key to the highest relaxivities, the results presented 
herein show that conventional wisdom doesn’t have it quite right.  Preparing two isomeric Gd3+ 
chelates with very similar electronic relaxation properties but very different water exchange 
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kinetics afforded the opportunity to undertake a direct side-by side comparison of the effect of 
changing water exchange kinetics on relaxivity.  Theory indicates that one chelate should have 
had vastly superior relaxivity: that should have been the one that exchanged water most rapidly 
(the TSAP isomer).  Instead what we observe is that the more slowly exchanging actually has 
substantially higher relaxivity.  Analysis of the relaxometric data reveals that the origin of this 
unique and unexpected result lies in a difference in hydration state (q/rGdH6) between the two 
isomers. The lower hydration state of the rapidly exchanging TSAP isomer and has a profoundly 
limiting effect on relaxivity. These results demonstrate that far from being a matter of little 
importance, the hydration state (number and position of water molecules in the inner 
coordination sphere) can have a very profound effect on relaxivity.  This demonstrates that, 
contrary to theory,simply ‘optimizing’ water exchange in Gd3+ chelates is no guarantee that very 
high relaxivitieswill be attained.  
 
Experimental 
General Remarks:  All solvents and reagents were purchased from commercial sources and 
used as received. HPLC purifications were performed on a Waters δ-Prep 150 HPLC system 
using a Phenomenex Luna C-18 reversed-phase (50 × 250 mm) column. In all cases absorbance 
was monitored at 205 and 254 nm.  The solvent system employed for the purification of chelates 
eluted with water (0.037 % HCl) for 5 minutes and then with a linear gradient to 80 %MeCN and 
20 % water (0.037% HCl) after 40 minutes, at a flow rate of 50 mLmin-1.  1H and 13C NMR 
spectra were recorded on a JEOL Eclipse 270 spectrometer at 270.17 MHz and 67.93 MHz, 
respectively or on a Varian Mercury 300 spectrometer operating at 300.01 MHz and 75.47 MHz, 
respectively. The 1/T1 nuclear magnetic relaxation dispersion profiles of water protons were 
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measured over a continuum of magnetic field strength from 0.00024 to 0.5 T (corresponding to 
0.01 – 20 MHz proton Larmor frequency) on the fast field-cycling StelarSpinmaster FFC 2000 
relaxometer equipped with a silver magnet.  The relaxometer operates under complete computer 
control with an absolute uncertainty in the 1/T1 values of ± 1%.  The typical field sequences used 
were the NP sequence between 40 and 8 MHz and PP sequence between 8 and 0.01MHz. The 
observation field was set at 13 MHz.  16 experiments of 2 scans were used for the T1 
determination for each field. Additional data at higher fields (30 - 70 MHz) were measured on a 
StelarSpinmasterrelaxometer equipped with a Brukerelectromagnet operating in the range 20 to 
80 MHz.  The synthesis of the ligands S-SSS-2 and S-RRR-2have been reported previously.33 
(4S,7S,10S)–α,α’,α’’-Trimethyl-[(S)-2-(4-aminobenzyl)]-1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (S-SSS-2) 
 The nitrobenzyl ligand S-SSS-1 (125 mg, 0.187mmol) was dissolved in water (10 mL) 
and 10 % palladium on carbon (20 mg) was added.  The reaction mixture was shaken on a Parr 
Hydrogenator apparatus for 12 h under H2 (25 psi).  The catalyst was removed by filtration and 
the solvents lyophilized to afford the title compound as a colourless solid (111 mg, 94 %). 
1H NMR (300 MHz, D2O pD 7), δ = 6.84 (2H, d, 3JH-H = 7 Hz, Ar), 6.62 (2H, d, 3JH-H = 7 Hz, 
Ar), 1.7-3.5 (22H, m br), 0.98 (9H, m, CH3); 13C NMR (75.5 MHz, D2O pD 7), δ = 7.3 (CH3), 
7.5 (CH3), 7.7 (CH3), 43.3, 45.1, 45.2, 46.9, 47.2, 47.4, 54.8, 56.9, 57.9, 58.0, 58.2, 58.5, 59.8, 
116.8 (Ar), 130.1 (Ar), 131.5 (Ar), 144.2 (Ar), 182.3 (CO2), 182.6 (CO2), 182.7 (CO2), 182.8 
(CO2); m/z (ESMS ESI+): 590 (8 %, [H4L +K]+), 612 (55 %, [NaH3L +K]+), 634 (71 %, 
[Na2H2L +K]+), 656 (100 %, [Na3HL +K]+); νmax / cm-1 (ATR / pH 7): 3338 (NH), 2968, 2829, 
1573 (CO2), 1462, 1408, 1258, 1227, 1166, 1126, 1032. 
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(4R,7R,10R)–α,α’,α’’-Trimethyl-[(S)-2-(4-aminobenzyl)]-1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (S-RRR-2) 
 The title compound was prepared from S-RRR-1 according to the procedure employed for 
S-SSS-2 and was isolated after removal of the solvents by lyopholization to afford a pale yellow 
solid (156 mg, 92 %). 
1H NMR (300 MHz, D2O pD 2), δ = 7.23 (4H, m, Ar), 2.6-4.1 (22 H, m br), 1.30 (9 H, m, 
CH3); 13C NMR (75.5 MHz, D2O pD 2), δ = 13.6 (2 × CH3), 14.5 (CH3), 31.7, 32.4, 46.7 (br), 
49.3 (br), 51.8, 53.4, 57.8, 58.7, 59.8, 61.6, 62.4 123.6 (Ar), 128.9 (Ar), 131.2 (Ar), 138.1 (Ar), 
172.1 (2 × C=O), 175.1 (C=O), 176.0 (C=O); m/z (ESMS ESI+): 552 (83 %, [H4L+H]+), 574 (45 
%, [H4L +Na]+) 590 (100 %, [H4L +K]+); νmax / cm-1 (ATR / pH 2): 3333 (NH), 2842, 2569, 
1713 (CO2H), 1620, 15556, 1540, 1506, 1473, 1455, 1207, 1163, 1099. 
(4S,7S,10S)–α,α’,α’’-Trimethyl-[(S)-2-(4-isothiocyanatobenzyl)]-1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (S-SSS-3) 
 The amine S-SSS-2 (108 mg, 0.170mmol) was dissolved in water (4 mL) and the pH of 
the resulting solution adjusted to 2 by addition of a dilute HCl solution.  Chloroform (6 mL) was 
added to the reaction which was then stirred vigorously at room temperature.  Thiophosgene (68 
mg, 0.59 mmol) was added to the reaction which was then stoppered and stirred vigorously for 
18 hours at room temperature.  The reaction mixture was then transferred to a separatory funnel 
and the chloroform layer was allowed to run off.  The aqueous layer was then washed with 
chloroform (2 x 15 mL).  The aqueous layer was then collected and the solvents removed under 
reduced pressure to afford the title compound as a colourless solid (111 mg, 95 %). 
1H NMR (300 MHz, D2O), δ = 7.35 (4H, m, Ar), 2.6 - 4.6 (22H, m br), 1.61 (3H, s br, 
CHCH3), 1.50 (3H, s br, CHCH3), 1.33 (3H, s br, CHCH3); m/z (ESMS ESI+): 594 (39 %, 
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[M+H]+), 616 (100 %, [M+Na]+), 532 (10 %, [M+K]+); νmax / cm-1: 3345 (OH), 2986, 2102 
(SCN), 1722 (C=O), 1516, 1455, 1394 1222, 1160, 1102, 1027; Anal. Found C = 44.8 %, H = 
6.3 %, N = 9.7 %, C27H39N5O9S·3(H2O) ·2(HCl) requires C = 45.0 % H = 6.6 % N = 9.7 %. 
(4R,7R,10R)–α,α’,α’’-Trimethyl-[(S)-2-(4-isothiocyanatobenzyl)]-1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (S-RRR-3) 
 The title compound was prepared from S-RRR-2 according to the procedure employed for 
S-SSS-3 and was isolated after removal of the solvents removed under reduced pressure to afford 
a colourless solid (127 mg, 93 %). 
1H NMR (300 MHz, D2O), δ = 7.15 (4H, m, Ar), 2.5-4.4 (22H, m br), 1.34 ( 9H, m, CH3); m/z 
(ESMS ESI-): 592 (100 %, [M-H]-); νmax / cm-1: 2924, 2098 (SCN), 1716 (C=O), 1558, 1520, 
1506, 1456, 1394, 1204, 1097. 
(4S,7S,10S)–α,α’,α’’-Trimethyl-[(S)-2-(4-[3-(biphenyl-4-
ylmethyl)thioureido]phenylmethyl)]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate 
gadolinium(III) chelate (H[Gd(S-SSS-4)]) 
 The isothiocyanateS-SSS-3 (102 mg, 0.150mmol) was dissolved in water (5 mL) and the 
pH of the solution adjusted to 8 (1M NaOH solution).  The solution was stirred at room 
temperature and a solution of 4-phenylbenzylamine (38 mg, 0.21 mmol) in dioxane (5 mL) was 
added.  The reaction mixture was stirred at room temperature for 18 hours.  A solution of 
gadolinium chloride hexahydrate (64 mg, 0.17 mmol) in water (2 mL) was then added to the 
reaction, the pH being maintained at 6 by periodic addition of a 1 M solution of NaOH.  The 
reaction was stirred at room temperature for 48 hours.  The solvents were removedin vacuo and 
the residue dissolved in a mixture of water and THF prior to HPLC purification.  After removal 
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of the HPLC eluent by lyophilisation the title compound was obtained as a colourless solid (58 
mg, 43%). 
HPLC RT = 32.77 min; m/z (ESMS ESI-): 930 (100 %, [GdL]-), the appropriate isotope pattern 
was observed; Anal. Found C = 46.9 %, H = 6.0 %, N = 8.0 %, C40H49N6O8SGd·5(H2O) requires 
C = 47.0 % H = 5.8 % N = 8.2 %. 
(4R,7R,10R)–α,α’,α’’-Trimethyl-[(S)-2-(4-[3-(biphenyl-4-
ylmethyl)thioureido]phenylmethyl)]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate 
gadolinium(III) chelate (H[Gd(S-RRR-4)]) 
The title compound was prepared from S-RRR-3 according to the procedure employed for 
GdS-SSS-4 and was isolated after removal of the solvents by lyophilisation to afford a colourless 
solid (49 mg, 39%). 
HPLC RT = 31.55 min; m/z (ESMS ESI-): 930 (100 %, [GdL]-), the appropriate isotope pattern 
was observed 
(4S,7S,10S)–α,α’,α’’-Trimethyl-[(S)-2-(4-[3-(biphenyl-4-
ylmethyl)thioureido]phenylmethyl)]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate 
europium(III) chelate (H[Eu(S-SSS-4)]) 
The title compound was prepared from S-SSS-3 and europium chloride hexahydrate according 
to the procedure employed for GdS-SSS-4 and was isolated after removal of the solvents by 
lyophilisation to afford a colourless solid (52 mg, 40%).  
HPLC RT = 33.73 min; 1H NMR (300 MHz, D2O), δ = 18.97 (NCH2-Hax), 17.93 (2H, NCH2-
Hax), 17.20 (NCH2-Hax), 8.35 – 6.0 (17H, m br, Ar and CH2Ar), 0.77 (NCH2-Heq), 0.84 (2H, 
NCH2-Heq), -0.56 (CH3), -1.11 (NCH2-Heq), -2.06 (CH3), -2.36 (NCH2-Hax), -2.74 (NCH2-Hax), -
3.04 (CH3), -3.99 (NCH2-Hax), -4.76 (NCH2-Hax), -5.18 (2H, NCH2-Heq) –5.48 (NCH2-Heq), -
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6.69 (Hac), -7.14 (Hac), -7.84 (Hac), -9.73 (Hac), -11.57 (Hac); m/z (ESMS ESI-): 925 (100 %, 
[EuL]-), the appropriate isotope pattern was observed; Anal. Found C = 41.5 %, H = 5.5 %, N = 
7.1 %, C40H48N6O8SEuNa·11(H2O) requires C = 41.9 % H = 6.1 % N = 7.3 %. 
(4R,7R,10R)–α,α’,α’’-Trimethyl-[(S)-2-(4-[3-(biphenyl-4-
ylmethyl)thioureido]phenylmethyl)]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate 
europium(III) chelate (H[Eu(S-RRR-4)]) 
The title compound was prepared from S-RRR-3 and europium chloride hexahydrate according 
to the procedure employed for GdS-SSS-4 and was isolated after removal of the solvents by 
lyophilisation to afford a colourless solid (44 mg, 37%). 
HPLC RT = 32.23 min; 1H NMR (300 MHz, D2O), δ = 37.99 (NCH2-Hax), 36.20 (NCH2-Hax), 
35.55 (NCH2-Hax), 35.34 (NCH2-Hax), 11.59 (1H, d, 2JH-H 7 Hz, NCHCH2Ar), 9.74 (1H, d, 2JH-H 
7 Hz, NCHCH2Ar), 8.45 (2H, aa′, 2JH-H 13 Hz, NHCH2Ar), 7.80 (3H, m, Ar), 7.76 (2H, d, 3JH-H 8 
Hz, para-substituted Ar), 7.67 (2H, t, 3JH-H 7 Hz, Ar), 7.44 (2H, d, 3JH-H 8 Hz, para-substituted 
Ar), 7.24 (2H, d, 3JH-H 8 Hz, para-substituted Ar), 7.03 (2H, d, 3JH-H 8 Hz, para-substituted Ar), 
1.51 (NCH2-Heq), 0.78 (NCH2-Heq), 0.27 (NCH2-Heq), -1.02 (NCH2-Heq), -2.92 (CH3), -3.73 
(CH3), -4.05 (CH3), -5.80 (NCH2-Hax), -6.06 (NCH2-Hax), -6.97 (NCH2-Hax), -7.66 (2H, NCH2-
Hax and NCH2-Heq), -9.90 (NCH2-Heq), -11.37 (NCH2-Heq), -12.70 (Hac), -14.64 (Hac), -19.50 
(Hac), -20.17 (Hac), -20.31 (Hac); m/z (ESMS ESI-): 925 (100 %, [EuL]-), the appropriate isotope 
pattern was observed. 
Molecular Modelling 
All modelling and docking procedures were carried out using the MOE molecular modelling 
package (MOE Version 2004.03 Chemical Computing Group Inc. Montreal, Canada).  The 
structures of the chelates of Gd4 were built from the crystal structure of the DOTA-type chelates 
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obtained from the Cambridge Structural Database (entry code JOPJIH; www.ccdc.cam.ac.uk/) 
and modelled using the Moe-Builder module keeping the Gd3+ coordination cage fixed.  
Conformational analysis of the isomeric Gd4 chelates was performed by a simulated annealing 
molecular dynamics (SAMD) method.  High-temperature MD calculations were carried out at 
1000 K with the starting velocities calculated from the Boltzmann distribution.  Each simulation 
ran for 2000 ps in steps of 0.1 fs with coordinates saved every 2ps resulting in 1000 
conformations.  Each conformation was subject to an energy-minimization step until 0.01 
convergence and then to a second molecular dynamic at 300 K for 20 interations, followed by 
conjugate gradient energy minimization until a convergence of 0.001. Clustering of 
conformations was performed by considering two identical conformers when their difference in 
energy was below 1 kcal mol-1 and their RMSD less than 3.0 Å.  The structure of β-CD was 
taken from the CSD (entry code BCDEXD10).  The high-resolution three-dimensional 
coordinates of human serum albumin (HSA) was obtained from the Protein Data Bank (PDB 
code 1E7H).  Prior to docking calculations the structures of HSA and β-CD were prepared by 
adding hydrogen atoms and completing missing atoms. The starting positions for the docking 
procedure were obtained by modifying the ligand positions and orientations to optimize binding 
geometry while filling the available space in the HSA drug sites I and II and in the β-CD cavity.  
Minimization was achieved by a multistep procedure, until convergence was less than 0.01 kcal 
mol-1 Å-1.  For all calculations a modification of the Amber99 force field79 was used with in-
house parameterization to treat Gd3+ chelates within the framework of the ionic method.48  The 
docking procedure was performed using the Moe-Dock module with Tabu Search with 10 runs, 
1000 steps per run. The ligand binding moiety was kept flexible during the docking calculations.  
For the β-CD docking the solvent was modelled by using a dielectric constant equal to 20, 
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whereas for the HSA docking an implicit solvation contribution (continuum model) was included 
to model solvent effects80 in the docking calculations. The results of the docking calculations 
were sorted by utilizing a force-field-based scoring function and for each isomer the five best 
poses were chosen comparing the interaction energies. 
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